Samuel Kintz Sells 12,500 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) Stock

by · The Cerbat Gem

Enliven Therapeutics, Inc. (NASDAQ:ELVN – Get Free Report) CEO Samuel Kintz sold 12,500 shares of the stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $20.83, for a total value of $260,375.00. Following the completion of the sale, the chief executive officer now owns 990,392 shares of the company’s stock, valued at approximately $20,629,865.36. This trade represents a 1.25 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Enliven Therapeutics Stock Up 3.0 %

Shares of NASDAQ ELVN traded up $0.61 during midday trading on Wednesday, hitting $20.89. The stock had a trading volume of 144,067 shares, compared to its average volume of 269,755. The company has a market cap of $1.02 billion, a P/E ratio of -10.99 and a beta of 1.04. Enliven Therapeutics, Inc. has a 52 week low of $14.50 and a 52 week high of $30.03. The business’s 50 day moving average is $21.45 and its 200-day moving average is $23.80.

Enliven Therapeutics (NASDAQ:ELVN – Get Free Report) last posted its quarterly earnings results on Thursday, March 13th. The company reported ($0.46) earnings per share for the quarter, topping the consensus estimate of ($0.53) by $0.07. The business had revenue of $0.03 million during the quarter. As a group, analysts expect that Enliven Therapeutics, Inc. will post -1.95 EPS for the current fiscal year.

Analysts Set New Price Targets

Separately, BTIG Research initiated coverage on Enliven Therapeutics in a report on Friday, December 13th. They set a “buy” rating and a $42.00 target price on the stock. Four equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Enliven Therapeutics presently has a consensus rating of “Buy” and an average target price of $38.25.

Get Our Latest Research Report on ELVN

Institutional Trading of Enliven Therapeutics

Institutional investors have recently made changes to their positions in the stock. Quest Partners LLC grew its position in Enliven Therapeutics by 1,226.4% in the 3rd quarter. Quest Partners LLC now owns 21,117 shares of the company’s stock worth $539,000 after purchasing an additional 19,525 shares during the period. First Turn Management LLC grew its holdings in shares of Enliven Therapeutics by 29.5% in the third quarter. First Turn Management LLC now owns 535,092 shares of the company’s stock worth $13,666,000 after acquiring an additional 121,849 shares during the period. Charles Schwab Investment Management Inc. increased its position in Enliven Therapeutics by 10.4% during the third quarter. Charles Schwab Investment Management Inc. now owns 255,277 shares of the company’s stock valued at $6,520,000 after acquiring an additional 24,043 shares during the last quarter. The Manufacturers Life Insurance Company boosted its position in Enliven Therapeutics by 25.6% in the third quarter. The Manufacturers Life Insurance Company now owns 17,282 shares of the company’s stock worth $441,000 after purchasing an additional 3,518 shares during the last quarter. Finally, FMR LLC boosted its holdings in shares of Enliven Therapeutics by 10.6% in the third quarter. FMR LLC now owns 6,296,179 shares of the company’s stock worth $160,804,000 after buying an additional 601,611 shares during the last quarter. Hedge funds and other institutional investors own 95.08% of the company’s stock.

About Enliven Therapeutics

(Get Free Report)

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.

See Also